Programme

Click on each session and speaker for further details

Each session aims to address a key problem in the breast cancer research field from both a clinical and research perspective through expert speakers, discussion and debate.

Day 1
15 Jan 2018
Day 2
16 Jan 2018

Session 1: Highlights of 2017

Basic:               Professor Clare Isacke

Translational:   Professor Peter Schmid

Early Disease:  Dr Michael Gnant

Late Disease:   Dr Mark Verrill

Professor Peter Schmid
Professor Peter Schmid
Dr. Michael Gnant
Dr Michael Gnant
Professor Clare Isacke
Professor Clare Isacke

Key Note Lecture: Dr Marc Lippman

Breast Cancer Research: Past and Future

Dr Marc Lippman
Dr Marc Lippman

Session 2: Metastatic Disease

Managing ER+ disease:                 
Professor Stephen Johnston

Predicting outcome in metastatic breast cancer: 
Dr Aleix Prat

Evolution of resistance:
Dr Adrian Harris

Dr. Aleix Prat
Dr Aleix Prat
Professor Stephen Johnston
Professor Stephen Johnston

Parallel Session 1: Ductal Carcinoma In Situ

How should we address overdiagnosis and overtreatment of DCIS?

Dr Laura Esserman

How wide a margin do we need for DCIS?

Professor Sarah Pinder

Should radiotherapy be routinely recommended after wide local excision of DCIS?

Professor David Dodwell

Abstract presentation

Dr. Laura Esserman
Dr Laura Esserman
Professor Sarah Pinder
Professor Sarah Pinder
Professor David Dodwell
Professor David Dodwell

Parallel Session 2: Model systems

PDX models:                                                            
Dr Rob Clarke

Organoid models:                                                    
Dr Mathew Garnett

3D in vitro modelling using material from Breast Cancer Now Tissue Bank: 
Dr Richard Grose

Dr Richard Grose
Dr Richard Grose
Dr. Mathew Garnett
Dr Mathew Garnett
Dr. Rob Clarke
Dr Rob Clarke

Key Note Lecture: Dr Laura Esserman

Innovation in neoadjuvant chemotherapy

Dr. Laura Esserman
Dr Laura Esserman

Session 3: Neoadjuvant Therapy

CHAIR: Andreas Makris

NAT as a surgical tool:                                  
Professor Mike Dixon

Treatment of the axilla post NACT:               
Dr Judy Boughey

RCB vs pCR as an end-point:                       
Dr Fraser Symmans

Latest data on imaging end points for NAT:  
Dr Sarah Vinnicombe

Dr. Fraser Symmans
Dr Fraser Symmans
Dr. Sarah Vinniecombe
Dr Sarah Vinnicombe
Professor Mike Dixon
Professor Mike Dixon

Parallel Session 4: Image analysis for scientists and pathologists

Imaging-based analysis of ErbB/HER signaling dimer and immunoregulatory molecules – from preclinical science to biomarker discovery
Professor Tony Ng
Image analysis for capturing stromal epithelial interaction
Dr Yinyin Yuan
Using digital pathology in translational breast cancer research
Professor Valerie Speirs

Dr. Yinyin Yuan
Dr Yinyin Yuan
Professor Valerie Speirs
Professor Valerie Speirs
Professor Tony Ng
Professor Tony Ng

Parallel Session 5: Novel Clinical Trial End-points

Why do we need better trial end-points?
Professor Judith Bliss
Novel trial endpoints: Opportunities and challenges for new surrogate endpoints
Dr Marc Buyse

Dr. Marc Buyse
Dr Marc Buyse
Judith Bliss
Professor Judith Bliss

Parallel Session 6: Costs of treatment

From price to value: Keeping breast cancer care affordable
Professor Richard Sullivan
Critically examining the true value of our therapies: The only way to meaningful gains in breast cancer
Dr Tito Fojo

Professor Richard Sullivan, Kings College London
Professor Richard Sullivan

Key Note Lecture: Professor Sir David Spiegelhalter

Understanding Risk

Professor Sir David Spiegelhalter
Professor Sir David Spiegelhalter

Key Note Lecture: Professor Jack Cuzick

Breast Cancer Prevention for the Population at Large

Professor Jack Cuzick
Professor Jack Cuzick

Session 1: Measuring and managing breast cancer risk

Stratification to Screening:                               
Professor Fiona Gilbert

Risk prediction for risk reduction:                     
Professor Gareth Evans

Findings from the Generations study:              
Professor Tony Swerdlow

Identifying genetic risk in the prevalent breast cancer population
Dr Nazneen Rahman

 

Professor Fiona Gilbert
Professor Fiona Gilbert
Professor Gareth Evans
Tony Swerdlow
Professor Tony Swerdlow

Parallel session 1: Triple Negative Breast Cancer

Biology of the new targets:  
Professor Andrew Tutt

Complexities of TNTs:         
Dr Chuck Perou

Immunologic advances:       
Dr Giuseppe Curigliano

 

Parallel session 2: Breast cancer heterogeneity and evolution

Genetic aspects:  
Dr Lucy Yates

Experimental modelling of heterogeneity:
Dr Rachael Natrajan

Relevance to the histopathologist:
Dr Fraser Symmans

 

Dr. Fraser Symmans
Dr Fraser Symmans
Dr. Rachel Natrajan
Dr Rachael Natrajan
Dr. Lucy Yates
Dr Lucy Yates

Session 2: New treatments and measuring their impact

CDK4/6i:          
Dr Nick Turner

New Selective Oestrogen Receptor Downregulators   
Dr Lesley-Ann Martin

Liquid biopsies:
Professor Jacqui Shaw

Professor Jacqui Shaw

Parallel session 3: Lobular breast cancer

Biologic aspects:
Dr Steffi Oesterreich

Genetic aspects:
Dr Elinor Sawyer

Histologic dilemmas
Professor Ian Ellis

Should lobular phenotype be considered when deciding treatment
Professor Michael Kerin

 

Dr. Steffi Oesterreich
Dr Steffi Oesterreich
Professor Michael Kerin
Professor Michael Kerin

Key Note Lecture: Chuck Perou

Completion of the Cancer Genome Atlas

Session 3: Biomarkers and prognostic profiling

Lessons from molecular subtyping:
Professor Carlos Caldas

Clinical utility of molecular profiles:
Professor Rob Stein

Identifying who needs extended adjuvant ET:
Dr Dan Hayes

Mutation-directed therapy:
Professor Fabrice Andre

 

Professor Rob Stein
Professor Rob Stein
Dr. Daniel Hayes
Dr Daniel Hayes
Professor Carlos Caldas
Professor Carlos Caldas
Professor Fabrice Andre
Professor Fabrice Andre

Parallel session 5: Challenges of local management

Management and follow up of patients presenting with breast cancer in axillary lymph nodes and occult breast primary:
Dr Andreas Makris

When is local surgery indicated in metastatic breast cancer:
Miss Nicola Roche

What is the impact of Magnetic Resonance Imaging (MRI) scanning on breast cancer treatment?
Dr Ulrich Bick

Current and future indications for partial breast radiotherapy:
Dr Charlotte Coles

 

Dr. Andreas Makris
Dr Andreas Makris
Miss Nicola Roche
Miss Nicola Roche
Dr. Charlotte Coles
Dr Charlotte Coles

Key Note Lecture: Professor David Cameron

Achievements of breast cancer research in the UK

Professor David Cameron
Professor David Cameron